Rory Shallis MD

PubMed

• 1 citations
  Feasibility and safety of outpatient hypomethylating agent and venetoclax initiation with and without ramp-up for newly diagnosed acute myeloid leukemia: results from ...
  Rory M Shallis, Julian J Weiss, Eric S Winer, Talha Badar, Alok Swaroop
  Leukemia & Lymphoma. 2025-09-01
• Real-world analysis of strategies to prevent thrombosis and bleeding in adults with ALL treated with asparaginase.
  Joseph F Mort, David Brighton, Benjamin Mautner, Eric Pierce, Farid Ghamsari
  Blood Vessels, Thrombosis & Hemostasis. 2025-08-01
• Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status.
  Talha Badar, James M Foran, Jan Philipp Bewersdorf, Yu-Hung Wang, Alexander Coltoff
  British Journal of Haematology. 2025-08-01

Abstracts/Posters

• The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and ...
  Rory M Shallis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin
  Rory M Shallis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Populati...
  Rory M Shallis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab
  Rory M Shallis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United State...
  Rory M Shallis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neopl...
  Rory M Shallis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019